×
About 1,073 results

ALLMedicine™ Lymphoblastic Lymphoma Center

Research & Reviews  364 results

Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lympho...
https://doi.org/10.1038/s41379-022-01085-9
Modern Pathology : an Official Journal of the United Stat... Bontoux C, Simonin M et. al.

May 14th, 2022 - In the latest 2016 World Health Organization classification of hematological malignancies, T-cell lymphoblastic lymphoma (T-LBL) and lymphoblastic leukemia (T-ALL) are grouped together into one entity called T-cell lymphoblastic leukemia/lymphoma ...

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

May 13th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT05290155

May 9th, 2022 - This study is single-armed,open lable,dose escalation clinical trial.The main purpose is to evaluate the safety and efficacy of anti-CD7 CAR-T cells in relapsed/refractory patients with CD7 positive T cell malignancies,including T lymphoblastic ...

Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First...
https://doi.org/10.1182/blood.2021014498
Blood Lu P, Liu Y et. al.

May 3rd, 2022 - Derivation of CD7-targeted chimeric antigen receptor (7CAR) T cells often requires genetic manipulations to ablate the CD7 gene or block CD7 cell surface expression. Our novel approach deriving naturally selected 7CAR-T cells (NS7CAR) from bulk T ...

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00408005

Apr 29th, 2022 - PRIMARY OBJECTIVES: I. To determine, through randomization, the relative safety and efficacy of the addition of nelarabine (Compound 506U78) to augmented Berlin-Frankfurt-Münster (BFM) therapy (Regimen C, Children's Cancer Group [CCG]-1961). II. T...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  32 results

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

May 13th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT05290155

May 9th, 2022 - This study is single-armed,open lable,dose escalation clinical trial.The main purpose is to evaluate the safety and efficacy of anti-CD7 CAR-T cells in relapsed/refractory patients with CD7 positive T cell malignancies,including T lymphoblastic ...

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00408005

Apr 29th, 2022 - PRIMARY OBJECTIVES: I. To determine, through randomization, the relative safety and efficacy of the addition of nelarabine (Compound 506U78) to augmented Berlin-Frankfurt-Münster (BFM) therapy (Regimen C, Children's Cancer Group [CCG]-1961). II. T...

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refr...
https://clinicaltrials.gov/ct2/show/NCT03384654

Apr 22nd, 2022 - Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by ...

Venetoclax Basket Trial for High Risk Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT05292664

Mar 23rd, 2022 - This is an investigator-initiated open-label multi-institutional phase I study of venetoclax combination therapy in both myeloid and lymphoid hematologic malignancies. This study is designed as a basket trial with three separate cohorts. All cohor...

see more →

News  29 results

Bortezomib Improves OS in Newly Diagnosed T-Cell Lymphoblastic Leukemia and Lymphoma
https://www.onclive.com/view/bortezomib-improves-os-in-newly-diagnosed-t-cell-lymphoblastic-leukemia-and-lymphoma

Apr 18th, 2022 - The addition of bortezomib (Velcade) to chemotherapy improved survival rates in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL), according to data from the phase 3 AALL1231 trial (NCT02112916) published in the J...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Children With Cancer At Higher Risk for Severe Illness from COVID-19
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient populati...

Kids With Cancer More Likely to Develop Severe COVID
https://www.medpagetoday.com/hematologyoncology/othercancers/94225

Aug 26th, 2021 - Children and adolescents with cancer and SARS-CoV-2 infection were more likely to develop severe and critical cases of COVID-19 compared with the general pediatric population, according to a global cohort study. Of children with cancer who contrac...

FDA Approves New Asparaginase Product for Leukemia
https://www.medscape.com/viewarticle/954149

Jul 2nd, 2021 - The US Food and Drug Administration (FDA) has approved a new version of asparaginase for use in children and adults who have developed hypersensitivity to asparaginase derived from Escherichia coli. The new product is Jazz Pharmaceutical's Rylaze ...

see more →